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andomised controlled trials are now underway in the general population to assess the impact of screening on ovarian cancer mortality. The United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) has recruited over 75,000 postmenopausal women from 13 centres in the UK (Figure 1 ). 200,000 women in all will be randomised to either control, screening with ultrasound or multi modal screening.
The use of three dimensional ultrasound, three dimensional power Doppler and colour Doppler as second line tests may help increase the specificity and reduce the number of false positives that result from an ultrasound based strategy. In a cohort of 90 women, transvaginal ultrasound, transvaginal color Doppler, three dimensional ultrasound and three dimensional power Doppler were performed during the week prior to surgery. Color Doppler studies added to transvaginal grayscale characterization of ovarian lesions and resulted in a sensitivity of 88.89% and specificity of 97.53% in diagnosing ovarian malignancy. Additionally, qualitative analysis of tumor vascularity by 3D power Doppler added to morphological features obtained by three dimensional ultrasound'. In a separate study, seventy-one women with a known complex pelvic mass were referred for a preoperative ultrasound evaluation with both two-dimensional and three-dimensional gray-scale ultrasonography. Two-dimensional gray-scale ultrasound identified 40 masses as suspicious for cancer, including all 14 malignancies, yielding a sensitivity, specificity, and positive predictive value of 100, 54, and 35%, respectively. However, evaluation with 3D power Doppler identified only 28 cases as suspicious (including all 14 cancers), resulting in a sensitivity, specificity, and positive predictive value of 100, 75, and 50%, respectively". In addition to these techniques that enhance and facilitate the morphologic and functional evaluation of both benign and malignant ovarian lesions, the problem of subjectivity of ultrasound, maybe overcome by self-teaching computer models such as neural networks" •.
Two distinct screening strategies have emerged, one blood based with measurement of the serum tumour marker as the primary test and ultrasound as the secondary test (multimodal screening) and the other ultrasound based with transvaginal scanning as the primary test.
Serum CA125 continues to be the tumour marker most extensively used in ovarian cancer screening. Sensitivity has been improved by developing a sophisticated approach to interpretation of CA125 results. In place of cut-off levels, a computerised algorithm assesses age of the women and her Transvaginal ultrasonography (lVS) is an integral component of all screening strategies for ovarian cancer. TVS is either used as the sole screening modality or as a secondary test following primary screening with the serum tumour marker CA 125. The aim is to detect the early architectural changes in the ovary that accompany carcinogenesis. Optimal sensitivity and specificity appear to be achieved by focussing on ovarian rnorpholoqy-. Most screening protocols use a weighted scoring system or morphological index based on ovarian volume, outline, presence of papillary projections and cyst complexity (i.e. number of locules, wall structure, thickness of septae and echogenecity of fluid). Persistence of ultrasound features on serial scanning is used to reduce false positive rates. The lack of physiological changes in ovarian volume in postmenopausal women improves the specificity in this group compared to pre-menopausal women.
Data from large prospective studies of ovarian cancer screening in the general population suggests that sequential multimodal screening has superior specificity and positive predictive value compared to strategies based on TVS alone. However ultrasound as a first line test may offer greater sensitivity for early stage disease although at a higher price In terms of surgical intervention for false positive results'.
Screening strategies
Ovarian cancer is the leading cause of death amongst women with gynaecological malignancies in developed nations. The increased survival advantage for patients diagnosed with early stage ovarian cancer suggests that screening to detect early stage disease might have an impact on disease mortality. In a randomised control trial of ovarian cancer screening using a multimodal screening strategy incorporating CA125 and ultrasound, median survival (72.9 months) was significantly increased in women with ovarian cancer In the screened group when compared to the control group (41.8 months)'.
The primary end point is impact of screening on ovarian cancer mortality. The study also addresses the issues of target population, compliance, health economics and physical and psychological morbidity of screening. Results are expected in ten years.
The Prostate. Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial has completed enrolling 74,000 women aged 55-74 at ten screening centers in the U.S.A. with balanced randomization to intervention and control arms. For ovarian cancer, women are screened using both CA125 and transvaginal ultrasound for three years and CA125 alone for a further two years. Follow-up will continue for at least 13 years from randomization to assess health status and cause of death".
Conclusion
Many aspects of ovarian cancer screening are still poorly understood, including whether or not there are precursor lesions, the rate of disease progression, and to what extent transvaginal ultrasonography and CA125 detect different cancers. Large randomised trials now underway in the general population while providing definitive data on impact of screening on mortality and screen associated morbidity will also resolve some of these issues. In the meanwhile there is great hope that as a result of gene expression and proteomic studies, a host of novel ovarian cancer markers will emerge that are highly sensitive and specific for the disease. 
